血液科指南

订阅

MedSci主页 / 所有栏目 / 血液科指南

2016 ISTH指南：使用直接口服抗凝剂治疗肥胖患者

2016-04-27 国际血栓与止血学会

口服抗凝剂肥胖

为临床医生就肥胖患者使用直接口服抗凝剂（DOACs）提供实用指导。

中文标题：

2016 ISTH指南：使用直接口服抗凝剂治疗肥胖患者

英文标题：

Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH

发布机构：

国际血栓与止血学会

发布日期：

2016-04-27

简要介绍：

为临床医生就肥胖患者使用直接口服抗凝剂（DOACs）提供实用指导。

相关资料下载：
[AttachmentFileName(sort=100, fileName=2016 ISTH指南：使用直接口服抗凝剂治疗肥胖患者)] GetToolGuiderByIdResponse(projectId=1, id=4aa991c001e795f9, title=2016 ISTH指南：使用直接口服抗凝剂治疗肥胖患者, enTitle=Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH, guiderFrom=, authorId=null, author=, summary=为临床医生就肥胖患者使用直接口服抗凝剂（DOACs）提供实用指导。, cover=, journalId=null, articlesId=null, associationId=405, associationName=国际血栓与止血学会, associationIntro=国际血栓和止血学会（ISTH）始建于1969年，是一个国际性的个人会员组织，成员来自世界各地，目前约有3000多个。其宗旨是通过会议、出版物和专家委员会制定相关的研究方法及标准等来提高血栓性及出血性疾病的医学教育和研究水平。, copyright=0, guiderPublishedTime=Wed Apr 27 00:00:00 CST 2016, originalUrl=, linkOutUrl=, content=<span style="color: rgb(46, 48, 51); font-family: Arial, 'Microsoft YaHei', 微软雅黑, 宋体, 'Malgun Gothic', Meiryo, sans-serif; font-size: 14px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 18px; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); display: inline !important; float: none;">为临床医生就肥胖患者使用直接口服抗凝剂（DOACs）提供实用指导。</span>, tagList=[TagDto(tagId=2729, tagName=口服抗凝剂), TagDto(tagId=332, tagName=肥胖)], categoryList=[CategoryDto(categoryId=21, categoryName=血液科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2634, appHits=101, showAppHits=0, pcHits=1168, showPcHits=1779, likes=50, shares=1, comments=6, approvalStatus=1, publishedTime=Wed Aug 14 18:13:27 CST 2019, publishedTimeString=2016-04-27, pcVisible=1, appVisible=1, editorId=5296140, editor=Vina2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=Vina2, createdTime=Wed Aug 14 18:13:27 CST 2019, updatedBy=null, updatedName=null, updatedTime=Sun Dec 31 06:37:09 CST 2023, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2016 ISTH指南：使用直接口服抗凝剂治疗肥胖患者)])
2016 ISTH指南：使用直接口服抗凝剂治疗肥胖患者
下载请点击：
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1055282, encodeId=95f210552823f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46445576118, createdName=枫语Lily, createdTime=Mon Sep 27 10:20:00 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954503, encodeId=c451954503cc, content=受益匪浅！好文章。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Wed Apr 07 13:11:08 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954659, encodeId=f77195465982, content=资料好好，但无法分享，遗憾！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bc65476534, createdName=ms6000001015893838, createdTime=Wed Apr 07 14:27:16 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888448, encodeId=e46388844862, content=好好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200926/009b5794eb6b420da6c6b6499b257c00/07eedfaa59094760b4e27d4def4712bf.jpg, createdBy=4f0c5296758, createdName=ms1000000003164590, createdTime=Sat Sep 26 06:38:32 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805479, encodeId=26c88054e9c2, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=200a5398171, createdName=ms5000001961239662, createdTime=Sat Aug 01 07:15:46 CST 2020, time=2020-08-01, status=1, ipAttribution=)]
    2021-09-27 枫语Lily

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1055282, encodeId=95f210552823f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46445576118, createdName=枫语Lily, createdTime=Mon Sep 27 10:20:00 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954503, encodeId=c451954503cc, content=受益匪浅！好文章。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Wed Apr 07 13:11:08 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954659, encodeId=f77195465982, content=资料好好，但无法分享，遗憾！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bc65476534, createdName=ms6000001015893838, createdTime=Wed Apr 07 14:27:16 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888448, encodeId=e46388844862, content=好好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200926/009b5794eb6b420da6c6b6499b257c00/07eedfaa59094760b4e27d4def4712bf.jpg, createdBy=4f0c5296758, createdName=ms1000000003164590, createdTime=Sat Sep 26 06:38:32 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805479, encodeId=26c88054e9c2, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=200a5398171, createdName=ms5000001961239662, createdTime=Sat Aug 01 07:15:46 CST 2020, time=2020-08-01, status=1, ipAttribution=)]
    2021-04-07 湘雅科教

    受益匪浅！好文章。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1055282, encodeId=95f210552823f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46445576118, createdName=枫语Lily, createdTime=Mon Sep 27 10:20:00 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954503, encodeId=c451954503cc, content=受益匪浅！好文章。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Wed Apr 07 13:11:08 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954659, encodeId=f77195465982, content=资料好好，但无法分享，遗憾！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bc65476534, createdName=ms6000001015893838, createdTime=Wed Apr 07 14:27:16 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888448, encodeId=e46388844862, content=好好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200926/009b5794eb6b420da6c6b6499b257c00/07eedfaa59094760b4e27d4def4712bf.jpg, createdBy=4f0c5296758, createdName=ms1000000003164590, createdTime=Sat Sep 26 06:38:32 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805479, encodeId=26c88054e9c2, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=200a5398171, createdName=ms5000001961239662, createdTime=Sat Aug 01 07:15:46 CST 2020, time=2020-08-01, status=1, ipAttribution=)]
    2021-04-07 ms6000001015893838

    资料好好，但无法分享，遗憾！

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1055282, encodeId=95f210552823f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46445576118, createdName=枫语Lily, createdTime=Mon Sep 27 10:20:00 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954503, encodeId=c451954503cc, content=受益匪浅！好文章。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Wed Apr 07 13:11:08 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954659, encodeId=f77195465982, content=资料好好，但无法分享，遗憾！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bc65476534, createdName=ms6000001015893838, createdTime=Wed Apr 07 14:27:16 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888448, encodeId=e46388844862, content=好好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200926/009b5794eb6b420da6c6b6499b257c00/07eedfaa59094760b4e27d4def4712bf.jpg, createdBy=4f0c5296758, createdName=ms1000000003164590, createdTime=Sat Sep 26 06:38:32 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805479, encodeId=26c88054e9c2, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=200a5398171, createdName=ms5000001961239662, createdTime=Sat Aug 01 07:15:46 CST 2020, time=2020-08-01, status=1, ipAttribution=)]
    2020-09-26 ms1000000003164590

    好好

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1055282, encodeId=95f210552823f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46445576118, createdName=枫语Lily, createdTime=Mon Sep 27 10:20:00 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954503, encodeId=c451954503cc, content=受益匪浅！好文章。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Wed Apr 07 13:11:08 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954659, encodeId=f77195465982, content=资料好好，但无法分享，遗憾！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bc65476534, createdName=ms6000001015893838, createdTime=Wed Apr 07 14:27:16 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888448, encodeId=e46388844862, content=好好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200926/009b5794eb6b420da6c6b6499b257c00/07eedfaa59094760b4e27d4def4712bf.jpg, createdBy=4f0c5296758, createdName=ms1000000003164590, createdTime=Sat Sep 26 06:38:32 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805479, encodeId=26c88054e9c2, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=200a5398171, createdName=ms5000001961239662, createdTime=Sat Aug 01 07:15:46 CST 2020, time=2020-08-01, status=1, ipAttribution=)]
    2020-08-01 ms5000001961239662

    好文章

    0

相关指南

2018 EHRA实践指导：房颤患者应用非维生素K拮抗剂口服抗凝药

欧洲心律学会(EHRA,European Heart Rhythm Association) · 2018-03-20

2016 ITAC-CME指南：直接口服抗凝剂治疗和预防癌症患者静脉血栓栓塞

国际血栓形成和癌症创议(ITAC-CME,International Initiative on Thrombosis and Cancer) · 2016-10-17